CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients.

Hodgkin's lymphoma (HL) is a hematological malignancy characterized by a minority of neoplastic cells outnumbered by tumor-associated macrophages (TAMs). The overexpression of the CD163 antigen by TAMs is considered to be a significant predictive biomarker for risk stratification. This is likely caused by a genetic single-nucleotide polymorphism (SNP) at the gene promoter.

Overall survival of classical Hodgkins lymphoma in Saudi patients is affected by XPG repair gene polymorphism.

In Hodgkin's lymphoma (HL), single nucleotide polymorphisms (SNPs) of specific DNA repair genes have been identified to have an important role in the risk of HL. Consequently, they may also serve an important role in HL prognosis and disease outcome. The present study aimed to define an SNP molecular profile, based on DNA repair genes mutations, as predictive biomarkers for the prognostic outcome of patients with Classical HL (CHL) in Saudi Arabia.